Ontario’s Ovensa Collaborates with Japan’s Takeda on Brain Medicine

Aurora, Ontario-headquartered Ovensa Inc. has entered into a collaboration agreement with Tokyo-based Takeda Pharmaceutical Company Limited to evaluate Ovensa's proprietary nanomedicine delivery platform, Triozan, for the delivery of an antibody to the brain and evaluate its performance in a central nervous system disease model. Takeda is the largest pharmaceutical company in Japan and is present in more than 70 countries. Ovensa’s Triozan delivery platform allows for the delivery of nanomedicines across the blood-brain barrier, with applications for reducing the side effects of chemotherapy, changing the expression of a gene that does not function normally, and boosting the immune response of antibodies in the brain.

Use 'AND' or 'OR' to refine your search.

Use quotes " " to get exact matches or remove them to get more results.